Brokerages Set Cryoport, Inc. (NASDAQ:CYRX) Target Price at $12.29

Shares of Cryoport, Inc. (NASDAQ:CYRX) have received an average recommendation of “Moderate Buy” from the seven brokerages that are covering the company, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $12.29.

CYRX has been the subject of a number of research reports. UBS Group lifted their target price on shares of Cryoport from $7.00 to $9.00 and gave the company a “neutral” rating in a report on Friday, October 18th. Guggenheim started coverage on Cryoport in a research report on Thursday, December 19th. They issued a “buy” rating and a $11.00 price target for the company. Finally, Roth Mkm reduced their price objective on shares of Cryoport from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, November 8th.

Cryoport Stock Performance

NASDAQ CYRX opened at $7.85 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.70 and a quick ratio of 5.32. Cryoport has a 1 year low of $5.32 and a 1 year high of $20.10. The stock has a market capitalization of $388.03 million, a PE ratio of -2.32 and a beta of 1.62. The company’s 50 day simple moving average is $7.45 and its two-hundred day simple moving average is $7.89.

Insiders Place Their Bets

In other news, CEO Jerrell Shelton sold 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $6.51, for a total value of $325,500.00. Following the completion of the sale, the chief executive officer now directly owns 731,897 shares of the company’s stock, valued at $4,764,649.47. This trade represents a 6.39 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ramkumar Mandalam sold 7,369 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $7.46, for a total value of $54,972.74. Following the sale, the director now owns 59,497 shares in the company, valued at approximately $443,847.62. The trade was a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 109,869 shares of company stock worth $735,673 over the last three months. Company insiders own 10.10% of the company’s stock.

Institutional Trading of Cryoport

Several institutional investors have recently added to or reduced their stakes in CYRX. Quest Partners LLC lifted its holdings in shares of Cryoport by 1,083,000.0% during the second quarter. Quest Partners LLC now owns 10,831 shares of the company’s stock valued at $75,000 after purchasing an additional 10,830 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Cryoport during the third quarter worth $82,000. Hsbc Holdings PLC purchased a new position in Cryoport in the second quarter valued at about $92,000. Intech Investment Management LLC acquired a new position in Cryoport in the 3rd quarter worth about $105,000. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Cryoport by 9.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 17,683 shares of the company’s stock valued at $122,000 after buying an additional 1,534 shares during the last quarter. Institutional investors own 92.90% of the company’s stock.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.